In colorectal cancer, histone lactation enhances the expression of the oncogene RUBCNL and promotes resistance to bevacizumab, a specific targeted therapy for anti-angiogenic genesis, in CRC[89]. This evidence concerns the gene RUBCNL and colorectal cancer.